Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler Halladay

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Biomedical Science|January 12, 2024
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategiesYan-Ruide Li, Tyler Halladay, Lili Yang
Nature Reviews. Immunology|May 16, 2025
In vivo CAR engineering for immunotherapyYan-Ruide Li, Yichen Zhu, Tyler Halladay, et al.
Cancer Cell|December 13, 2024
Breaking the mold: Unconventional T cells in cancer therapyYan-Ruide Li, Kuangyi Zhou, Yichen Zhu, et al.
Nature Protocols|January 17, 2025
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation cultureYan-Ruide Li, Kuangyi Zhou, Derek Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 14, 2025
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safetyYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Cell Reports. Medicine|August 30, 2025
Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cellsYan-Ruide Li, Junhui Hu, Zhe Li, et al.
ACS Chemical Neuroscience|January 5, 2026
In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau FibrilsHope Pan, Xinyi Cheng, Jeffrey Zhang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Biomedical Science|January 12, 2024
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategiesYan-Ruide Li, Tyler Halladay, Lili Yang
Nature Reviews. Immunology|May 16, 2025
In vivo CAR engineering for immunotherapyYan-Ruide Li, Yichen Zhu, Tyler Halladay, et al.
Cancer Cell|December 13, 2024
Breaking the mold: Unconventional T cells in cancer therapyYan-Ruide Li, Kuangyi Zhou, Yichen Zhu, et al.
Nature Protocols|January 17, 2025
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation cultureYan-Ruide Li, Kuangyi Zhou, Derek Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 14, 2025
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safetyYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Cell Reports. Medicine|August 30, 2025
Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cellsYan-Ruide Li, Junhui Hu, Zhe Li, et al.
ACS Chemical Neuroscience|January 5, 2026
In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau FibrilsHope Pan, Xinyi Cheng, Jeffrey Zhang, et al.
Pageof 1